In a report published Monday, Morgan Stanley analyst David Risinger downgraded the rating on Mylan (NASDAQ: MYL) …
25.08.2006 Mylan Labs sell Banc of America Sec. 25.08.2006 Update Mylan Laboratories Inc.: Sell Banc of America Sec. 30.06.2006 Mylan Labs Ersteinschätzung Crédit Suisse Um die Übersicht zu verbessern, haben Sie die Möglichkeit, …
Mylan's shares dropped after it said that delays in launching key new drugs and lower prices for generics in the United States will hurt its profitability this and next year. Fred Katayama reports.
Pharmaceutical firm Mylan NV has been hit with a new proposed class action lawsuit in the U.S. over the price of its EpiPen allergy treatment, which shot up to more than $600 US for a two-pack of the device from less than $100 in …
CBC5mon
Otsuka Pharmaceutical Co. Ltd. and Mylan N.V. have entered into a licence pact through their units — Otsuka Novel Products GmbH and Mylan Pharmaceuticals Pvt. Ltd. — to commercialise Delamanid for the treatment of adults with …
Billionaire hedge fund manager John Paulson, who became a household name during the Great Recession for a hugely successful short on subprime mortgages, increased his ownership of Mylan NV to 4.5% or 22 million shares. John …
Yahoo is now part of ‘Oath’ and a member of the Verizon family of companies. As of 15 September 2017, we plan to share some user information within our new family. Learn more
Up Last 7 Days N/A N/A N/A N/A Up Last 30 Days N/A N/A N/A N/A Down Last 30 Days N/A N/A N/A N/A Down Last 90 Days N/A N/A N/A N/A
Next 5 years (per annum) 5.10% N/A N/A 0.10 Past 5 years (per annum) 14.89% N/A N/A N/A